BiotechTube

4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Phase 3Recruiting
2 views this week 0 watching⚡ Active🔬Featured in Small-Cap Pipeline Watch
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Macular Neovascularization Secondary to Age-Related Macular Degeneration

Conditions

Macular Neovascularization Secondary to Age-Related Macular Degeneration

Trial Timeline

Mar 3, 2025 → Jun 1, 2028

NCT ID
NCT06864988

About 4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL)

4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL) is a phase 3 stage product being developed by 4D Molecular Therapeutics for Macular Neovascularization Secondary to Age-Related Macular Degeneration. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06864988. Target conditions include Macular Neovascularization Secondary to Age-Related Macular Degeneration.

What happened to similar drugs?

20 of 20 similar drugs in Macular Neovascularization Secondary to Age-Related Macular Degeneration were approved

Approved (20) Terminated (3) Active (0)
✅FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
✅FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
✅Aflibercept Injection [Eylea]Santen PharmaceuticalApproved
✅Ozurdex + AfliberceptAbbVieApproved
✅RanibizumabNovartisApproved
✅ranibizumabNovartisApproved
✅intravitreal injection of Brolucizumab 6 mg in study eyeNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07064759Phase 3Recruiting
NCT06864988Phase 3Recruiting

Competing Products

20 competing products in Macular Neovascularization Secondary to Age-Related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
25
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
4 mg CLS-TA + Sham + IVT afliberceptClearside BiomedicalPhase 2
25
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or AvastinClearside BiomedicalPhase 3
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
KVD001 InjectionKalVista PharmaceuticalsPhase 2
29
KVD001 InjectionKalVista PharmaceuticalsPhase 1
23
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
33
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 2
25
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 1
19
CT-P42 + EyleaCelltrionPhase 3
40
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
40
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
40
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Fovista® + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
27
MA09-hRPEAstellas PharmaPre-clinical
26